Table 3.
Adverse effects according to treatment groups
| Parameter | Week 0 – week 12 | Week 13 – week 52 | |||
|---|---|---|---|---|---|
| Ixekizumab n (%) | Secukinumab n (%) | Ixekizumab n (%) | Secukinumab n (%) | ||
| Common adverse reactions: | |||||
| Mild to moderate infections | 44 (28.39) | 39 (24.68) | 47 (30.32) | 45 (28.85) | |
| Headache | 19 (12.26) | 19 (12.03) | 26 (16.77) | 18 (11.39) | |
| Nasopharyngitis – sinusitis | 11 (7.09) | 15 (9.49) | 33 (21.29) | 23 (14.56) | |
| Upper RTI – bronchitis | 7 (4.52) | 10 (6.33) | 29 (18.71) | 19 (12.03) | |
| Pruritus | 3 (1.94) | 7 (4.43) | 11 (7.09) | 8 (5.06) | |
| Fatigue | 6 (3.87) | 8 (5.06) | 8 (5.16) | 5 (3.16) | |
| Arthralgia – back pain | 11 (7.09) | 6 (3.80) | 13 (8.39) | 12 (7.59) | |
| Cough | 5 (3.23) | 9 (5.70) | 4 (2.58) | 7 (4.43) | |
| Gastroenteritis (diarrhoea, nausea, abdominal pain) | 14 (9.03) | 7 (4.43) | 5 (3.23) | 8 (5.06) | |
| Serious adverse reactions: | |||||
| Infections | 1 (0.65) | 1 (0.63) | 4 (2.58) | 2 (1.27) | |
| Cardiac/vascular | 0 (0.00) | 0 (0.00) | 2 (1.29) | 1 (0.63) | |
| Renal and urinary | 0 (0.00) | 0 (0.00) | 1 (0.66) | 0 (0.00) | |
| Gastrointestinal | 1 (0.66) | 1 (0.63) | 2 (1.29) | 2 (1.27) | |
| Others | 0 (0.0) | 2 (1.27) | 6 (3.87) | 7 (4.43) | |
| Hematologic laboratory abnormalities: | |||||
| Decreased neutrophils | 0 (0.0%) | 0 (0.0%) | 2 (1.29) | 3 (1.89) | |
| Decreased lymphocytes | 0 (0.0%) | 0 (0.0%) | 1 (0.66) | 2 (1.27) | |
| Elevated ALT/SGPT | 1 (0.66) | 2 (1.27) | 3 (1.94) | 3 (1.89) | |
| Elevated AST/SGOT | 0 (0.0%) | 1 (0.63) | 1 (0.66) | 2 (1.27) | |